State-of-the-art Therapy for Glioblastoma Multiforme

a report by
Henry S Friedman, MD

James B Powell Jr Professor of Neuro-oncology, Duke University Medical Center

The treatment of patients with glioblastoma multiforme (GBM) is conventionally considered to be a palliative venture with no hope of cure. Traditionally, patients are treated with maximal surgical resection based on the premise that, although surgery is not a curative procedure, a major resection provides for a longer survival and better quality of life. Radiotherapy increases the duration of survival, but again is not a curative intervention. The role of chemotherapy, specifically focusing on a foundation of chloroethylating agents such as carmustine (BCNU) or lomustine (CCNU), has been controversial with an equal number of clinicians arguing in favor of or against this treatment. Meta-analysis makes it clear that there is a small increase in median survival associated with the addition of these agents, but a consensus was never reached regarding their use.

Unfortunately, the underlying assumption of virtually all clinicians that GBM is not a curable tumor led to a wide spectrum of interventions utilized in the community to treat these patients. Many patients received a biopsy rather than a major resection of their tumor. Despite the lack of evidence supporting whole-brain versus focal radiotherapy, some patients received (or still receive) whole-brain radiotherapy with the associated increased morbidity. Finally, community and academic physicians chose to not use chemotherapy without a firm foundation of data to support withholding it. A positive step forward started with the synthesis and evaluation of temozolomide and subsequent phase I and II trials with this methylating agent in the UK. Temozolomide was shown to have activity in phase I trials in two patient populations: those with malignant glioma or those with melanoma. Subsequent phase II trials in the UK confirmed this activity, leading Schering Plough to license the drug for studies in the US. Following phase I trials in adults and children, a pivotal registration trial—as well as a trial of newly diagnosed patients with GBM with residual disease following initial surgical intervention or biopsy intervention—were initiated. The first published study by Friedman et al. demonstrated the profound activity of temozolomide in patients with newly diagnosed GBM with a response rate exceeding 50%. Although the registration trial for patients with first-relapse GBM demonstrated a near tripling of the six-month progression-free survival, concerns voiced by the US Food and Drug Administration (FDA) regarding this as a legitimate end-point prevented the approval of temozolomide for this indication. However, the one-arm study evaluating temozolomide in the treatment of patients with first-relapse anaplastic astrocytoma led to an accelerated approval for this agent.

Roger Stupp took the next step forward by building on the results of the prior studies of temozolomide. A one-arm trial was initiated of 65 patients who received surgery then radiation with daily temozolomide, followed by six cycles of traditional five-days-a-month temozolomide. These results showed a provocative survival curve leading to a randomized phase III trial in patients with newly diagnosed GBM. The results confirmed the benefit of temozolomide, which produced a modest increase in survival for patients receiving this agent. Overnight, temozolomide became the global standard of care. Ironically, an agent producing a very similar increase in survival—notably Gliadel wafers, which release BCNU into a tumor cavity following their implantation—has not been as universally accepted. Although this may have initially reflected concerns with toxicity—due to a lack of appreciation of the need for a watertight dural seal following placement of these wafers—and the initially unfavorable cost, at least in the US, it is now clear that both of these problems have been addressed and the use of this agent appears to be increasing.

The problem that we currently face in the field is the continued belief that patients with GBM will die, and therefore our efforts are merely...
Patients not on a clinical trial can also be treated with off-label commercially available agents, particularly if other studies will evaluate these agents in formal clinical trials, so we are not slowing the progress of the field, but offering patients hope who are not on a trial. An example of this would be the use of Bevacizumab, which in recent years has demonstrated its role in newly diagnosed GBM.\(^\text{12}\)

An additional concern that has arisen following the universal acceptance of temozolomide has been the role of O6-methylguanine-DNA methyltransferase (MGMT)—also known as O6-alkylguanine DNA alkyltransferase—in making decisions regarding the use of temozolomide. A series of clinical studies have clearly demonstrated the role of this protein in predicting response to temozolomide. Friedman et al.\(^\text{1}\) showed this first in the upfront study of patients with newly diagnosed GBM. Roger Stupp built on this with subsequent trials further defining the relationship between MGMT and temozolomide. Unfortunately, it is not an all or nothing relationship, particularly when using the promoter methylation assay. It is clear that any recommendations to use or not use temozolomide based on this assay are inappropriate. Maxwell et al.\(^\text{14}\) clearly demonstrated that even in a situation where the methylation assay actually showed a lack of methylation of the promoter, there is still a population of cells that do not stain for MGMT and, therefore, are likely to be sensitive to temozolomide. The appropriate recommendation when the MGMT promoter is not methylated is not to withhold temozolomide, but to use it while including additional agents that will not be susceptible to this protein. Of course, we argue that additional agents should always be used, and never rely on temozolomide alone as a single agent.

Patients with glioblastoma multiforme are not universally incurable with an ever-increasing, albeit small, fraction of patients who appear to survive the disease.

---